NYSEMKT:IGC IGC Pharma (IGC) Stock Price, News & Analysis $0.34 -0.01 (-2.85%) (As of 09/18/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartFinancialsSEC Filings Get IGC Pharma alerts: Email Address About IGC Pharma Stock (NYSEMKT:IGC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get IGC Pharma alerts:Sign Up Key Stats Today's Range$0.33▼$0.3550-Day Range N/A52-Week Range N/AVolume516,163 shsAverage Volume390,008 shsMarket Capitalization$25.74 millionP/E RatioN/ADividend YieldN/APrice Target$3.75Consensus RatingBuy Company OverviewIGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.Read More… Central Bank Abandons USD (Ad)Startling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold. Click here now to get your free 'Protect Your Wealth' Guide. IGC Pharma Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 24th PercentileIGC Pharma scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingIGC Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageIGC Pharma has only been the subject of 1 research reports in the past 90 days.Read more about IGC Pharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of IGC Pharma is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IGC Pharma is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIGC Pharma has a P/B Ratio of 3.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for IGC. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIGC Pharma does not currently pay a dividend.Dividend GrowthIGC Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for IGC. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows4 people have added IGC Pharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, IGC Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders19.00% of the stock of IGC Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 3.87% of the stock of IGC Pharma is held by institutions.Read more about IGC Pharma's insider trading history. Receive IGC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IGC Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address IGC Stock News HeadlinesIGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's TreatmentSeptember 18 at 7:35 PM | finance.yahoo.comThe Analyst Verdict: IGC Pharma In The Eyes Of 4 ExpertsSeptember 4, 2024 | benzinga.comWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.September 18, 2024 | Porter & Company (Ad)IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's DiseaseSeptember 4, 2024 | finance.yahoo.comBioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Announces Stockholders’ Approval of All Disclosed Proposals at 2024 Annual MeetingAugust 27, 2024 | msn.comIGC Announces Results of its 2024 Annual Stockholders MeetingAugust 27, 2024 | finance.yahoo.comSee More Headlines IGC Stock Analysis - Frequently Asked Questions How have IGC shares performed this year? IGC Pharma's stock was trading at $0.4039 at the start of the year. Since then, IGC shares have decreased by 15.7% and is now trading at $0.3403. View the best growth stocks for 2024 here. How do I buy shares of IGC Pharma? Shares of IGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Today9/18/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEMKT SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSEMKT:IGC CUSIPN/A CIK1326205 Webigcpharma.com Phone(301) 983-0998Fax240-465-0273Employees67Year FoundedN/APrice Target and Rating Average Stock Price Target$3.75 High Stock Price Target$3.75 Low Stock Price Target$3.75 Potential Upside/Downside+1,002.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,000,000.00 Net Margins-1,252.64% Pretax Margin-1,252.64% Return on Equity-138.75% Return on Assets-110.26% Debt Debt-to-Equity Ratio0.02 Current Ratio1.77 Quick Ratio1.16 Sales & Book Value Annual Sales$1.06 million Price / Sales24.24 Cash FlowN/A Price / Cash FlowN/A Book Value$0.11 per share Price / Book3.09Miscellaneous Outstanding Shares75,636,000Free Float61,265,000Market Cap$25.74 million OptionableN/A Beta1.27 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report This page (NYSEMKT:IGC) was last updated on 9/18/2024 by MarketBeat.com Staff From Our PartnersChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored625,000% GainThe recent crypto correction has shaken many investors, causing panic and uncertainty. But while others are fr...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IGC Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IGC Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.